Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. November 2016 07:00 ET | Quelle: Kamada Ltd.

Kamada Announces Collaboration Agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin

NESS ZIONA, Israel, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA) a plasma-derived protein therapeutics company focused on orphan indications, announced today...
10. November 2016 07:00 ET | Quelle: Kamada Ltd.

Kamada Reports Financial Results for the Third Quarter and Nine Months of 2016

Total Revenues for Third Quarter 2016 Grew 21% to $19.4 Million vs. Third Quarter 2015 Proprietary Products Revenue Grew 57% to $15.0 Million in Third Quarter 2016 vs. Third Quarter 2015 ...
07. November 2016 07:00 ET | Quelle: Kamada Ltd.

Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment

PDUFA goal date of August 29, 2017If approved, product would represent new treatment option in $100M-plus market where supply of post-exposure rabies treatment has been inconsistent over timeFORT LEE,...
03. November 2016 08:00 ET | Quelle: Kamada Ltd.

Kamada to Host Third Quarter Financial Results Conference Call on November 10, 2016 at 8:30 am Eastern Time

NESS ZIONA, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release...
02. November 2016 07:30 ET | Quelle: Kamada Ltd.

Kamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease

NESS ZIONA, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced the...
06. Oktober 2016 06:30 ET | Quelle: Kamada Ltd.

Kamada Announces Extension of GLASSIA® Supply and Distribution Agreement with Shire with Minimum $237 Million of Revenue for the Years 2017 to 2020

NESS ZIONA, Israel, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the...
09. September 2016 08:00 ET | Quelle: Kamada Ltd.

Kamada to Present a Corporate Overview at the Rodman & Renshaw 18th Annual Investment Conference

NESS ZIONA, Israel, Sept. 09, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that...
01. September 2016 06:30 ET | Quelle: Kamada Ltd.

Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment

Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDAOn approval by FDA, the...
30. August 2016 06:30 ET | Quelle: Kamada Ltd.

Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency

Company’s Inhaled AAT Demonstrated Significant Increase in Endothelial Lining Fluid Inhibitory Capacity Study Results Also Showed that Inhaled AAT is the Most Efficient Way of Delivering...
02. August 2016 06:30 ET | Quelle: Kamada Ltd.

Kamada Reports Financial Results for the Second Quarter and First Six Months of 2016

Total Revenues for First Half of 2016 Grew 20% to $33.9 Million vs. First Half of 2015 Proprietary Products Revenue Grew 46% to $23.2 Million in First Half of 2016 vs. First Half of 2015 Company...

Vorherige Seite